BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonnet U, Juckel G, Scherbaum N, Schaefer M, Kis B, Cohen S, Kuhn J. Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19? Pharmacopsychiatry 2021;54:142-3. [PMID: 33733436 DOI: 10.1055/a-1408-8298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Mueller JK, Riederer P, Müller WE. Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? Pharmacopsychiatry 2022;55:7-15. [DOI: 10.1055/a-1717-2381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bauer M, Juckel G. Covid-19: Contributions from Psychopharmacology. Pharmacopsychiatry 2022;55:5-6. [DOI: 10.1055/a-1720-8855] [Reference Citation Analysis]
3 Bonnet U, Claus B, Schaefer M, Kuhn J, Nyhuis P, Scherbaum N, Brüne M, Wakili V, Juckel G. Impact of Psychiatric and Related Somatic Medications on the Duration and Severity of COVID-19: A Retrospective Explorative Multi-center Study from the German Metropolitan Ruhr-area. Pharmacopsychiatry 2021. [PMID: 34530483 DOI: 10.1055/a-1559-3904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]